Immunocore completed 540-patient enrollment. Immunocore stock fell 1.90 percent.

Published on 10/08/2026 at 17:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

KIMMTRAK sales rose 16.00 percent in the first half of 2026. Immunocore stock costs EUR 25.80 on October 8, 2026 after EUR 26.30.

Key points in brief

Immunocore completed enrollment of 540 patients in the TEBE-AM Phase 3 trial on September 14, 2026.
KIMMTRAK sales reached USD 223.00 million in the first half of 2026, up 16.00 percent year over year.
The stock was trading at EUR 25.80 after hours at Lang & Schwarz on October 8, 2026, down 1.90 percent from EUR 26.30.
Topline TEBE-AM data could arrive as early as the end of 2026.

IMCR, US45258D1054, Illustration mit AI erstellt.

Immunocore (ISIN US45258D1054) completed target enrollment of 540 patients in its TEBE-AM Phase 3 trial on September 14, 2026, according to Immunocore. The stock was trading at EUR 25.80 after hours at Lang & Schwarz on October 8, 2026, down 1.90 percent versus the prior close of EUR 26.30.

Three milestones shape the pipeline

On June 1, 2026, Immunocore reported median overall survival of 14.30 months in a Phase 1/2 advanced melanoma study, as listed by Zonebourse.

On August 6, 2026, KIMMTRAK net sales reached USD 223.00 million in the first half of 2026, representing 16.00 percent growth from the first half of 2025, according to Benzinga. On September 14, 2026, the company reported the 540-patient enrollment milestone in TEBE-AM.

What does enrollment mean for timing?

Immunocore said patients will continue to be followed for the planned overall survival analysis, with topline data possible as early as the end of 2026. The company described TEBE-AM as a randomized Phase 3 trial testing KIMMTRAK alone, KIMMTRAK with pembrolizumab, and investigator choice in previously treated advanced melanoma.

The study's primary endpoint is overall survival, so the enrollment milestone starts the follow-up phase rather than delivering a result by itself. The potential market significance rests on whether the trial can extend KIMMTRAK beyond its approved uveal melanoma use and into a population of up to 4,000 HLA-A*02:01-positive patients in the United States and Europe, a figure stated in the September 14 release.

Dates investors are watching

Benzinga reported that TEBE-AM topline data could arrive as early as the end of 2026. The same earnings-call transcript places an HIV program update in the first half of 2027, giving the pipeline two separate timing markers beyond commercial KIMMTRAK sales.

Stock trades lower after hours

At Lang & Schwarz, Immunocore stock was trading at EUR 25.80 on October 8, 2026 at 5:48 p.m. CEST, down 1.90 percent from the EUR 26.30 prior close on October 7, 2026. The primary exchange is Nasdaq, where the company trades under IMCR, and its 52-week range was USD 27.55 to USD 40.72 as of October 8, 2026.

The further course of trading is shown by the continuously updated real-time quote of Immunocore stock.